A phase 1, open-label study evaluating the pharmacokinetics, safety, and tolerability of vepdegestrant in Chinese patients with ER+/HER2- advanced breast cancer.

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

http://www.ncbi.nlm.nih.gov/pubmed/42593688

Binghe Xu; Cong Fei; Fei Guan; Huadong Zhao; Jin Yang; Liang Zhang; Naihan Chen; Pin Zhang; Wenna Wang; Xiao'ai Zhao

Aug 14, 2026